Ultimovacs ASA – Mandatory notification of trade
Reference is made to the stock exchange announcement by Ultimovacs ASA (the “Company”) on 17 December 2024 regarding the agreement…
Pharmaceuticals, Biotechnology and Life Sciences
Reference is made to the stock exchange announcement by Ultimovacs ASA (the “Company”) on 17 December 2024 regarding the agreement…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR…
Tuesday, December 17, 2024 at 8:00 am ESTREDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”)…
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in…
Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal…
Vote “FOR” All Four Kellner Group Nominees Today on Gold Card for Urgently Needed Change Kellner Group Owns 5.04% of…
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s…
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE…